erlotinib hydrochloride has been researched along with Hypertension in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Callies, S; Gao, L; Garon, EB; Nakagawa, K; Reck, M; Visseren-Grul, C; Walgren, R; Zimmermann, A | 1 |
| Alonso Garcia, M; Fabre, E; Frimodt-Moller, B; Garon, EB; Moro-Sibilot, D; Nadal, E; Nakagawa, K; Novello, S; Ponce Aix, S; Reck, M; Visseren-Grul, CM; Zimmermann, AH | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Davisson, RL; Eguchi, S; Elliott, KJ; Forrester, SJ; Fukuda, Y; Kawai, T; Obama, T; Park, JY; Takayanagi, T; Tilley, DG; Tsuji, T | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
3 trial(s) available for erlotinib hydrochloride and Hypertension
| Article | Year |
|---|---|
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypertension; Lung Neoplasms; Mutation; Ramucirumab | 2022 |
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Mutation; Placebos; Progression-Free Survival; Ramucirumab; Response Evaluation Criteria in Solid Tumors; Survival Rate; United States; Young Adult | 2021 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
3 other study(ies) available for erlotinib hydrochloride and Hypertension
| Article | Year |
|---|---|
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II.
Topics: ADAM Proteins; ADAM17 Protein; Angiotensin II; Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Endothelium, Vascular; ErbB Receptors; Erlotinib Hydrochloride; Hypertension; Hypertrophy; Mice; Muscle, Smooth, Vascular; Phenylbutyrates; Quinazolines; Random Allocation; Role; Sensitivity and Specificity; Signal Transduction; Vascular Remodeling | 2015 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |